微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 58.11% | -3.35% | -1.57% | 54/159 | 48.66% | 民生健康 | 54.64% | 行业排名> |
| 2026-03-31 | 59.03% | -2.47% | 1.76% | 59/159 | 50.28% | 海创药业 | 97.34% | 行业排名> |
| 2025-12-31 | 58.01% | 1.3% | -2.18% | 57/159 | 50.37% | 海创药业 | 99.82% | 行业排名> |
| 2025-09-30 | 59.31% | 1.44% | -1.35% | 53/159 | -2.12% | 海创药业 | 98.62% | 行业排名> |
| 2025-06-30 | 60.12% | 2.78% | -0.68% | 52/159 | 15.05% | 海创药业 | 99.57% | 行业排名> |
| 2025-03-31 | 60.53% | 3.68% | 5.69% | 47/159 | 31.79% | 海创药业 | 99.52% | 行业排名> |
| 2024-12-31 | 57.27% | 0.57% | -2.04% | 59/159 | 51.61% | 艾力斯 | 96.74% | 行业排名> |
| 2024-09-30 | 58.46% | 2.35% | -0.05% | 55/159 | 22.43% | 首药控股 | 98.96% | 行业排名> |
| 2024-06-30 | 58.49% | 1.19% | 0.2% | 56/159 | 32.96% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-03-31 | 58.38% | 4.9% | 2.52% | 53/159 | 51.47% | 百利天恒 | 97.99% | 行业排名> |
| 2023-12-31 | 56.95% | 2.7% | -0.31% | 64/159 | 51.31% | 百利天恒 | 98.92% | 行业排名> |
| 2023-09-30 | 57.12% | 3.08% | -1.18% | 63/159 | 32.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-06-30 | 57.81% | 2.2% | 3.87% | 61/159 | 38.22% | 迈威生物 | 99.59% | 行业排名> |
| 2023-03-31 | 55.65% | -1.65% | 0.37% | 65/159 | 52.66% | 迈威生物 | 99.8% | 行业排名> |
| 2022-12-31 | 55.45% | -0.58% | 0.06% | 73/159 | 53.51% | 迈威生物 | 99.46% | 行业排名> |
| 2022-09-30 | 55.42% | -4.1% | -2.03% | 69/159 | 5.67% | 迈威生物 | 99.75% | 行业排名> |
| 2022-06-30 | 56.56% | -2.71% | -0.04% | 68/159 | 20.91% | 迈威生物 | 99.67% | 行业排名> |
| 2022-03-31 | 56.59% | -4.55% | 1.46% | 65/159 | 54.06% | 迈威生物 | 99.44% | 行业排名> |
| 2021-12-31 | 55.77% | -11.5% | -3.48% | 71/159 | 54.9% | 迈威生物 | 98.57% | 行业排名> |
| 2021-09-30 | 57.78% | -9.98% | -0.61% | 58/159 | 46.49% | 首药控股 | 99.93% | 行业排名> |
| 2021-06-30 | 58.14% | -10.39% | -1.93% | 61/159 | 46.97% | 艾力斯 | 99.41% | 行业排名> |
| 2021-03-31 | 59.28% | -6.39% | -5.92% | 52/159 | 53.79% | 艾力斯 | 98.7% | 行业排名> |
| 2020-12-31 | 63.01% | -0.65% | -1.83% | 55/159 | -147.51% | 艾力斯 | 99.4% | 行业排名> |
| 2020-09-30 | 64.19% | -0.32% | -1.07% | 43/159 | 56.06% | 首药控股 | 99.94% | 行业排名> |
| 2020-06-30 | 64.88% | 0.77% | 2.45% | 41/159 | 53.85% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-03-31 | 63.33% | -1.1% | -0.16% | 40/159 | 54.83% | 微芯生物 | 95.14% | 行业排名> |
| 2019-12-31 | 63.43% | 0.12% | -1.49% | 49/159 | -1232.76% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-09-30 | 64.39% | -0.46% | 0.02% | 36/159 | 54.86% | 微芯生物 | 95.81% | 行业排名> |
| 2019-06-30 | 64.38% | -0.46% | 0.54% | 39/159 | 54.88% | 微芯生物 | 96.09% | 行业排名> |
| 2019-03-31 | 64.03% | -0.52% | 1.08% | 34/159 | 50.75% | 微芯生物 | 96.11% | 行业排名> |
| 2018-12-31 | 63.35% | 10.31% | -2.07% | 45/159 | -210.26% | 微芯生物 | 95.5% | 行业排名> |
| 2018-09-30 | 64.69% | 13.43% | 0.02% | 29/159 | 53.75% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 64.68% | 15.53% | 0.49% | 30/159 | 53.16% | 贝达药业 | 95.47% | 行业排名> |
| 2018-03-31 | 64.36% | 17.1% | 12.07% | 32/159 | 53.78% | 贝达药业 | 95.51% | 行业排名> |
| 2017-12-31 | 57.43% | 8.13% | 0.7% | 49/159 | 52.25% | 贝达药业 | 95.54% | 行业排名> |
| 2017-09-30 | 57.03% | 8.31% | 1.87% | 33/159 | 48.76% | 贝达药业 | 95.74% | 行业排名> |
| 2017-06-30 | 55.99% | 7.91% | 1.86% | 35/159 | 47.61% | 退市金泰 | 96.19% | 行业排名> |
| 2017-03-31 | 54.96% | 11.42% | 3.49% | 31/159 | 46.62% | 贝达药业 | 95.81% | 行业排名> |
| 2016-12-31 | 53.11% | 2.39% | 0.86% | 41/159 | 48.17% | 退市金泰 | 95.93% | 行业排名> |
| 2016-09-30 | 52.66% | 0.87% | 1.49% | 28/159 | 45.83% | 贝达药业 | 95.58% | 行业排名> |
| 2016-06-30 | 51.88% | -2.69% | 5.18% | 33/159 | 45.93% | 贝达药业 | 95.89% | 行业排名> |
| 2016-03-31 | 49.33% | -10.5% | -4.9% | 26/159 | 43.86% | 微芯生物 | 97.46% | 行业排名> |